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ABSTRACT
The control of crystallization steps is essential in the production of many materials in the
pharmaceutical, materials, and chemical industries. Additionally, due to increasing costs of
research and development, reductions in manufacturing costs by moving from batch to
continuous manufacturing are necessary to sustain profitability of the pharmaceutical industry.
Two different projects were researched to progress towards this goal. The first was the
demonstration of a continuous manufacturing platform. The second goal was the development of
new crystallization techniques.
Two continuous crystallization processes were developed as part of a demonstration unit
for continuous manufacturing of Aliskiren hemifumarate. The first process was an anti-solvent
crystallization of an intermediate. The second process was a continuous reactive crystallization
developed for the final product. The processes were able to crystallize the two compounds with
both high yield (>90%) and purity (>99%). Population balance modeling was performed and
experimental data were fit to the model to obtain kinetic parameters for crystal growth and
nucleation for both systems. The models were used to optimize crystal purity and yield of the
products.
In addition, this thesis describes two separate projects involving spherical agglomerates.
In the first study, acetaminophen was shown to crystallize significantly faster in the presence of
spherical agglomerates of lactose than single crystal lactose. An epitaxy study and molecular
dynamics simulations showed that the (14T)/(001) pairing of faces showed coincident lattice
matching and favorable energy interaction. Maximizing the number of substrate faces available
for interaction increases the chance for a lattice match between the substrate and the crystallizing
material which can be useful for controlling and increasing nucleation kinetics.
Finally, water-in-oil emulsions were used to make composite spherical agglomerates with
two components: a heterosurface, and a target compound that does not typically crystallize as
spherical agglomerates on its own. The generated composite agglomerates were relatively
monodisperse and were characterized using optical microscopy, scanning electron microscopy,
x-ray powder diffraction, and differential scanning calorimetry. This technique could potentially
be applied to other hydrophilic compounds, in particular water-soluble pharmaceuticals
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compounds, in order to change crystal morphology to spherical agglomerates in order to simplify
downstream processing.
Thesis Supervisors:
Bernhardt Trout
Title: Professor of Chemical Engineering
T. Alan Hatton
Title: Ralph Landau Professor of Chemical Engineering
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1. INTRODUCTION
1.1. Need for Continuous Manufacturing
The cost of manufacturing pharmaceuticals has becoming increasingly expensive over the
recent years. A study performed in 2003 by Dimasi showed the ever increasing cost of research
and development of new drugs, and showed that it increased significantly faster than the rate of
inflation, and faster than the rate of new drug discovery [1]. In addition, the increased prevalence
of generics companies has increased competition and reduced sales volumes for drug innovators
[2, 3]. Because of rising costs of discovery and research, once a drug has actually been
developed, reducing the production costs as much as possible is paramount to retaining
profitability. Manufacturing costs can account for up to 30% of the total cost of producing a
pharmaceutical product [3]. If this amount can be reduced significantly, the profitability of
producing drugs can be increased. Continuous manufacturing is seen as one of the leading ways
to decrease production costs while maintaining or even improving drug quality. Significant
research has already been done to develop new technologies that could be used to continuously
produce pharmaceutical products. This includes work studying new methods to perform
reactions [4-6], crystallizations [7, 8], and downstream processing [9-12]. Crystallizations in
particular are an area where significant progress can be made to improve downstream processing.
1.2. Crystallization Background
Crystallization is an important separation and purification process for a number of
products in a multitude of industries. Many manufacturing processes in industries such as
chemicals, foods, and pharmaceuticals include a crystallization step as either an intermediate
purification or final isolation step [13]. Crystallization processes are designed to obtain crystals
with controlled purity, size, shape, and polymorphic form in high yield. For final crystallization
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steps of pharmaceutical products, the control of crystal size, shape, and form is crucial as these
properties can influence downstream operations such as filtration, drying, and milling as well as
influence the physical and chemical properties such as dissolution rate and solubility [14, 15].
Additionally, purity and yield of the product are very important parameters, the prior to ensure
that the product meets specification, the latter to maximize production. Knowledge of the process
conditions required to fabricate crystals with controlled characteristics is critical during process
development.
Pharmaceutical crystallizations are typically performed in batch, using cooling, addition
of anti-solvent, and reaction to generate supersaturation. Although the methodologies for
developing these types of batch crystallization processes are reasonably well understood, there
are still significant issues with batch-to-batch variability which can lead to substantial issues in
the downstream processing of the isolated material [16-18]. There exists significant potential to
transform the entire industry by producing these products via continuous
manufacturing. Continuous manufacturing has the potential for increases in efficiency, flexibility,
and quality through the use of process analytical technology. Crystallization have been identified
as key elements in improving manufacturing in the chemical and pharmaceutical industries [19].
There are two major areas that need to be researched for the conversion of batch
processing to continuous. The first is to research ways to convert processes to continuous using
existing technology. The second is to develop new technologies and techniques to perform these
unit operations. Figure 1-1 shows a schematic of a current typical drug manufacturing process
(top) and a proposed new method of manufacturing drugs (bottom).
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Chemical/ API Batch API lTableting
Solution CrysCrystals Encpsu
New Drug Manufacturing Process
Chemical/ API Continuous 
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_ API-Excipient Tableting/Biological So > >
Synthesis Solution Crystallization Purification Mixture Encapsulation
Figure 1-1: Flow chart of current and proposed drug manufacturing process
One major issue with continuous downstream processing is that performing unit operations with
significant solids handling like continuous granulation, blending, and mixing can be difficult. In
order to facilitate this process, removing these steps by performing crystallizations in which the
final product is more amenable for downstream processing would be advantageous.
Both of these research projects have been studied and are presented in this thesis. Two
continuous crystallizations processes were developed using existing MSMPR crystallizers.
Additionally, evaporative emulsion crystallizations were performed to make spherical
agglomerates for two purposes. The first aim was to make spherical agglomerates of excipients
to use as surfaces for heterogeneous nucleation of API's. The second aim was to make composite
spherical agglomerates which would be more amenable for direct processing.
1.3. Continuous Crystallization
The focus of the Novartis-MIT Center for Continuous Manufacturing is the development
of new technologies that will allow continuous pharmaceutical manufacturing. One of the
important milestones for the center has been the development of a demonstration unit for
continuous manufacturing. This work describes the two continuous crystallizations that were
developed as part of this demonstration unit.
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The most common types of continuous crystallizers are mixed-suspension, mixed
product-removal (MSMPR) and plug-flow crystallizers. Models for both types developed by
Randolph and Larson (1971) have been used extensively by various investigators for the
simultaneous determination of nucleation and growth kinetics in crystallization systems [7, 18,
20-23]. Both MSMPR and plug-flow crystallizers have their advantages, but plug-flow
crystallizers are usually used for fast growing systems with low residence times [7]. The
compounds used in this study are slow growing and thus have long residence times. For the
system being studied, MSMPR crystallizers were found to be more appropriate. This paper
investigates experimentally and through modeling the cascaded MSMPR multistage
crystallization system developed to perform a continuous reactive crystallization.
Two different compounds were studied in this work. Both are crystallization steps from
the manufacturing of Aliskiren Hemifumarate. Aliskiren Hemifumarate is a renin inhibitor
approved for the treatment of hypertension. It was approved for sale by the FDA in 2007 and is
sold under the trade names Tekturna and Rasilez. This API was chosen as the model compound
because it was observed that there were many areas of the manufacturing process that could
greatly benefit from switching from batch processing to continuous processing. One of the
crystallizations studied is for an intermediate purification (Aliskiren boc-base), while the second
crystallization is a simultaneous reaction and crystallization of the final active pharmaceutical
ingredient (Aliskiren Hemifumarate). The batch processes for both of the crystallizations are
highly complex with high throughput times. The continuous crystallization systems described
herein are shown to significantly reduce the throughput time without compromising process yield
or purity [24, 25].
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1.4. Spherical agglomerates as surfaces for heterogeneous nucleation
One means for controlling such properties is through the use of heterogeneous nucleation.
Heterogeneous nucleation is nucleation in the presence of a surface or an interface. It has been
used in conjunction with organic crystals, polymers, and self-assembled monolayers (SAMs) to
manipulate crystallographic orientation and to control the nucleation of different polymorphs
[26-3 1]. Heterogeneous nucleation can also significantly increase nucleation rates. It has been
shown that tuning specific chemistries on polymeric surfaces by modulating mesh sizes can
change the induction time of aspirin by 4 orders of magnitude [32-34]. In another study, Form I
of acetaminophen (AAP) crystallized in the presence of single crystals of a-lactose monohydrate
and D-mannitol was shown to nucleate approximately five times faster than AAP nucleated from
the bulk [35]. The reduction in induction time was due to a functional group match between AAP
and lactose and mannitol rather than a purely geometric lattice match - the substrate and AAP
having complementary functional groups allowed for significant hydrogen bonding at the
interface. This was demonstrated by crystallizing AAP in the presence of graphite, whose (100)
face shares a coincident lattice match with certain faces of Form I AAP. Although graphite
decreased the induction time by a factor of 2 when compared to bulk nucleation, graphite was
not as effective as a-lactose monohydrate or D-mannitol. These studies highlight the importance
of considering both lattice matching and molecular functionality when designing heterogeneous
crystallizations.
Although single crystal substrates have been shown to increase the nucleation rate of AAP,
modifying the crystal morphology may further enhance nucleation kinetics. For example, Carter
et al. [14] and Bonafede et al. [15] demonstrated how the presence of two contact planes reduces
the activation barrier for nucleation more than just one contact plane. Exposing many additional
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crystal faces through modulation of the crystal morphology could induce improved nucleation
behavior. One method of fabricating substrates with modified morphologies is to crystallize them
as spherical agglomerates. Spherical agglomerates of substrates tend to be composed of densely
packed single crystals [36, 37]. Scanning electron microscope images from different studies have
shown that spherical agglomerates have increased surface roughness compared with their
corresponding single crystals, and may also exhibit differences in their morphologies [36-39].
In the present study, we have explored how crystallizing certain substrates as spherical
agglomerates can alter their surface morphology which may lead to crystal faces being exposed
that are not present in the equilibrium single crystal morphology. The effect that these
differences in crystal morphology may have on heterogeneous nucleation kinetics was then
explored. Spherical agglomerates of triclinic lactose and D-mannitol were crystallized using a
previously developed evaporative water-in-oil emulsion technique [40]. The surface morphology
and diffraction patterns of the agglomerates were characterized using image analysis and X-ray
powder diffraction, respectively. If new peaks were present in the diffraction patterns of the
agglomerates they were assigned miller indices by comparing them to peaks from calculated
powder patterns. The effect of the morphology changes and newly available crystal faces on the
induction time of AAP was then measured. Lattice matching software (EpiCalc) and molecular
dynamics simulations were used to rationalize these effects in terms of epitaxial ordering and
favorable interactions between the substrate and AAP. Finally, with the discovery of new lattice
matches and chemistries on the surfaces of the agglomerates we are able to explain the
differences between the nucleation behaviors [27, 41, 42].
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1.5. Composite spherical agglomerates
In addition to enhancing nucleation kinetics, spherical particles or agglomerates have a
number of physical properties that are beneficial for downstream processing. Some crystal
morphologies such as needles can adversely affect the downstream operations of filtration,
drying, and compression, and can also affect physical properties such as dissolution rate and
solubility. Many earlier studies have shown that spherical agglomerates of API's are easier to
filter, have better flowability, and often are more compatible for direct compression [36-38, 43,
44] than single crystals or powders. Much of the previous work on spherical crystallization or
agglomeration was based on the use of a 3-solvent system to enact agglomeration of crystals, as
described by Kawashima [39, 45-48]. Spherical particles of glycine have been made using
evaporation from monodisperse microemulsions [49]. Spherical particles have also been
obtained through the growth of crystalline agglomerates inside water-in-oil emulsion droplets
through the slow evaporation of the droplets to generate supersaturation of the dissolved
substance, allowing time for the nucleation and growth of these spherical agglomerates. This
technique has been used to prepare spherical agglomerates of glycine and glutamic acid
hydrochloride [40]. This approach did not work for all systems investigated, however; ephedrine
hydrochloride, for instance, crystallized in the continuous phase rather than in the droplets. In
other cases, nucleation occurred within the droplet, but as single crystals rather than as the
desired spherical agglomerates of small crystallites with their better dissolution properties. It
would be beneficial to develop a more robust, general method for generating spherical
agglomerates to expand the range of API's to this approach for the enhancement of processing
and physical properties may be applied; in this work, we show that heterogeneous nucleation
within the confined droplets may be exploited to improve the spherical agglomeration process.
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Heterogeneous nucleation is that which occurs in the presence of an interface or surface,
which can affect nucleation behavior significantly [26, 27, 30, 31, 50], and not in the bulk
solution. It has been shown that crystallization experiments performed in the presence of
polymeric surfaces with various chemistries can reduce the induction time for the nucleation of
aspirin and acetaminophen [32-34, 51]. In another study, acetaminophen crystals were shown to
nucleate significantly faster in the presence of both lactose and mannitol than when nucleated
homogeneously, attributed to extensive hydrogen bonding at these heterogeneous interfaces [35].
These studies demonstrate that by the selective choice of the surface and its properties,
nucleation kinetics can be enhanced significantly. We show here that it is possible to use
heterogeneous surfaces to modify the morphology of material crystallized inside emulsion
droplets.
Glycine (as demonstrated before) and lactose were readily crystallized as spherical
agglomerates and thus served as good heterosurfaces for the templating of D-Mannitol, sodium
chloride, and potassium chloride, which were identified as good targets for morphology
modification.. The resulting composite spherical agglomerates were characterized using multiple
analytical techniques. This work demonstrated that water-in-oil crystallizations with
heterosurfaces can be used to prepare spherical agglomerates of materials that otherwise would
not crystallize as such.
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2. EXPERIMENTAL
2.1. Materials
Mannitol, sodium chloride, potassium chloride, glycine, fumaric acid, dodecane, span 20,
span 80, hexadecyltrimethylammonium bromide, ethyl acetate, and hexane (all 99% or higher)
were purchased from Sigma Aldrich. a-Lactose monohydrate (99% pure) was purchased from
Emprove. Ethanol (200 proof) was purchased from VWR International. Deionized water was
produced using a Millipore Milli-Q system. Aliskiren lactone (Cl), amino-dimethyl-
propionamide, Aliskiren boc-base (C2), and Aliskiren free base (C3) were received from
Novartis. The Aliskiren free base was received dissolved in ethanol, so in order to get it into a
usable form, the ethanol was evaporated using a roto-vap, and the free base was re-suspended in
ethyl acetate.
2.2. Analytical Techniques
Focused beam reflectance measurement [FBRM] was used to detect nucleation and to
measure chord length distributions (CLD) of the solid product [52, 53]. The FBRM device was a
Lasentec S400 probe from Mettler Toledo, with a measurement range from 785 nm to 1000 pm.
X-ray powder diffraction (XRPD) patterns were recorded with a PANalytical X'Pert PRO
Theta/Theta Powder X-ray Diffraction System with a Cu tube and X'Celerator high-speed
detector. This technique was used to identify crystal forms, determine polymorphism, and
analyze crystallinity. Differential Scanning Calorimetry (DSC) was used to analyze crystallinity
of crystals and for compound identification. DSC measurements were performed using a Q5000
DSC from TA instrument.
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Crystal morphology was observed by a Zeiss Axiovert 200 optical microscope in
transmission mode with a differential interference contrast polarizer and magnification range
from 5x to 50x. Prior to collection of Scanning Electronic Microscope (SEM) images with a
JEOL 6060 SEM at a 5 kV operating voltage, the samples were sputter coated with a Quorum
Technologies SC7640 high resolution gold/palladium sputter coater. Concentration and purity
were measured using High Performance Liquid Chromatography (HPLC). Mother liquor
samples were taken using PTFE syringe filters with 0.2 iL pore size. An HPLC instrument
(Agilent Technologies 1200 Series) with a column Nucleosil 100-3 C18 (4.0 X 125 mm, 3 pm)
was utilized for measuring the concentration at 230 nm, using an Agilent 1200 Series UV
detector. Measuring conditions were flow rate: 1.0 mL/min, injection volume: 20 pL, and
temperature: 50 'C.
2.3. Crystallization of Aliskiren Boc-base
Multistage continuous crystallization experiments were carried out in a self-assembled
multistage crystallization system. Each stage was operated as a MSMPR crystallizer. The
experimental system consisted of two 50 milliliter (mL) glass jacketed crystallizers with
independent temperature control and overhead mechanical stirring. Feed solution containing C1
was continuously pumped into the first crystallizer using a peristaltic pump (flow rate range
0.006 - 600 mL/min, MasterFlex, provided by Cole-Parmer corporation). In this study, two
different configurations were studied. In the first configuration - Configuration A -
supersaturation was generated in the first vessel using cooling and supersaturation was generated
in the second vessel using both cooling and anti-solvent addition. For Configuration B,
supersaturation was generated in the first vessel using both anti-solvent and cooling, and the
second vessel was cooled even further. Schematics of the experimental setup can be seen in
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Figure 2-1. The suspension that was generated in the first crystallizer was transferred to the
second stage using a peristaltic pump. The temperature of both vessels was controlled +/- O.14C
with a NESLAB RTE Refrigerated Bath Circulator.
C2 solution
Stage 1 Stage 2
Heptane Anti-solvent
Stage 1
C2 solution
Stage 2
Heptane Anti-solvent
Figure 2-1: Schematic Diagram of Continuous Crystallization Apparatus for C2
The concentrations of C1 and C2 in the feed material and mother liquor were measured
by high performance liquid chromatography (HPLC). Mother liquor samples were taken by
filtering slurry samples from each vessel using PTFE syringe filter with 0.2 pL pore size.
Anti-solvent cooling continuous crystallization experiments for C2 were performed using
the continuous crystallization apparatus described in Figure 2-1. The feed solution consisted of
EtOAc with 13% (m/m) C2 at room temperature, 2% (m/m) Cl, and 1% (m/m) impurities that
were generated in the synthesis of C2. The feed solution was directly pumped into the first
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crystallizer at a flow rate 0.125 mL/min. The working volume of the first stage was 30 mL and
the residence time of each stage was set to 4 hours. The slurry in the first crystallizer was then
pumped into the second crystallizer. Concurrently an anti-solvent stream of heptane was added to
the vessel. The heptane flow rate was set such that it would comprise 25% (m/m) of the solvent
mass (0.036 mL/min). The temperatures of Stages 1 and 2 were -5"C, and -100C, respectively.
The duration of the experiment was 33 hours (four total residence times). The concentration of
the mother liquor and the chord length distribution were both monitored over time. Once the
signals leveled out, steady state was reached.
2.4. Crystallization of Aliskiren Hemifumarate
A schematic of the continuous crystallization set-up used for experimentation can be seen
in Figure 2-2. The system has two 50 mL mixed suspension mixed product removal (MSMPR)
crystallizers in series. Each is jacketed for temperature control and has independent overhead
stirring. Material is pumped into and out of each vessel using peristaltic pumps.
C3 solution
250C
Vessel 1: 200C Vessel 2: -10"C
Fumaric Acid
solution 70*C
Figure 2-2: Continuous Crystallization Apparatus for Aliskiren Hemifumarate
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In a typical experiment, ethyl acetate containing 6 w/w% Aliskiren free base was pumped
into the first vessel. Concurrently, an ethyl acetate / ethanol solution (50/50 w/w%) containing 5
w/w% fumaric acid was also pumped into the first vessel. The C1 - ethyl acetate mixture is
maintained at room temperature. The fumaric acid solution was kept separately at 70'C to
solubilize the fumaric acid. A molar ratio of 0.58 moles fumaric acid to 1 mole free base was
used to produce the hemifumarate salt. The slight excess was to ensure that all of the free base
reacted with fumaric acid to form the hemifumarate. Though the free base is freely soluble in
ethyl acetate, the hemifumarate salt is much less soluble and spontaneously nucleates. The
temperature of the first stage of the crystallization is 20'C, and the slurry is then pumped into the
second vessel which operates at -10'C. This second vessel is used for further nucleation and
growth of the crystals. Each vessel has a 4 hours residence time. The temperature of each vessel
was controlled to +/- 0.1 C with a NESLAB RTE Refrigerated Bath Circulator.
2.5. Equilibrium Impurity Distribution Coefficients
The distribution of the impurity between the solid and liquid phases at each stage of
crystallization is determined by the Distribution Coefficient [8, 54], which can be also expressed
as: [54]
DC = (1)(c, /C c,
A mass balance for the impurity over a stage j has terms for the impurity coming in (Cij.1, and
Mij.1 ), a term for the impurity going out in solution (Cij ), and a term for the impurity
accumulated in the crystals (Mi,)
Cw 1 M _1 = C +M (2)
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Where Ci. 1 , and Mij.1 are the concentrations of impurity in liquid and solid phase entering stage
j, and Cij, and Mij are the concentrations of impurity in liquid and solid phase leaving stage j.
From the experimental data shown in Figure 8, the Distribution Coefficient at each stage
is a function of the concentration of impurity, which can be expressed as follows:
DC =a CJ + +b (3)
Where a and b are experimental parameters.
Substituting equation (3) into (1) to eliminate DCj, and substituting into (2) yields a quadratic
expression, from which the concentration of impurity at stage j can be calculated:
c 2 i-1b 1 - a j +Ci 1 j(Ct'_1 + M 1 _ - C,] - bMAI ]+ CAl (C C_1 ± M _1 )- = 0 (4)
CA,j CA,j_
Finally, purity of the host compound is calculated as the mass faction of the host in the solid
phase
Mass of Product
Purity(%) = ((Mass of Product + Mass of impurity)
In order to measure distribution coefficients, a sequence of crystallization experiments
was carried out. For the C1 crystallization, a series of anti-solvent and cooling crystallization
experiments was performed. Heptane was added to a saturated solution of Cl in EtOAc at 25 0C
in increments of 5% heptane by mass up to a total of 25% heptane. The solution was then cooled
to -100C in increments of 5'C. For C3, sufficient fumaric acid was added to react completely
with the freebase at 250C, and cooling crystallization experiments were subsequently performed
in 50C increments down to -1 00C. After each of these crystallization experiments, the crystallized
solids were separated by filtration and dried overnight. Samples of solids and mother liquor were
analyzed by HPLC to determine distribution coefficients.
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When impurities incorporate at small level into the crystal, the incorporation can be
characterized by a distribution coefficient which is defined as the ratio of impurity
concentrations to the host compound concentration in the solid phase divided by that ratio in the
liquid phase.
2.6. Population Balance Modeling
Final crystal properties including yield, purity, morphology, and particle size are important
for the success of a crystallization process. A model relating nucleation and crystal growth
kinetics to operating variables is necessary to evaluate the effect of operating conditions on all of
these properties. A model of the continuous crystallization process based on the simultaneous
solution of the Population Balance Equation (PBE) and Mass Balance Equation has been
developed [8]. The purpose of the model is to predict the crystal purity, yield, and size
distribution of the crystals obtained in the multistage cascaded continuous crystallization system
[13, 18, 21, 55, 56]. FBRM was employed to determine the particle size distribution for the
parameter estimation of the model in the current work. The crystals from both of the
crystallization processes described have needle-like morphology. Because FBRM does not
directly measure the particle size distribution, the particle size distributions from the model and
experimental were not precisely the same [13, 21]. Thus, the fitted growth and nucleation
parameters are not exactly correct values. The model, however, is still useful tool to study the
effects of operating conditions on the purity and yield. Other published work has used CLD
measurements from FBRM directly in modeling rather than converting it to a particle size
distribution first [8, 57, 58]. Equilibrium distribution coefficients were also included in the model
to give information about crystal purity.
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Assuming a clear feed stream into the first stage, the general population balance equations
can be reduced to
Gjirj r + nj =0 (6)dL 1(6
rdn(7
G2 12 d2 + n2 = n (7)2 dL
Where L is the characteristic size of the crystal, n(L) is the number density of crystals per unit
volume of size between L and L+dL, G is the size-independent crystal growth rate, and r is the
mean residence time. These equations can be solved analytically using the boundary condition:
n(O)=no, where n0 is the crystal density of zero size nuclei. The analytical solution is
0 (- L)n, = nj exp yj (8)
n2 =n2 expL + no exp - exp  (9)2 2eXPG2T2 IGIrI - G2 T2 .. GIrI G2T2_
The rate at which solute is lost from the solution phase is equal to the rate at which mass is
gained by the solid phase. Thus, a mass balance on the solute crystallized in each stage gives:
Co = C1 + MTi for stage 1,
And, C1 = C2 + MT2 for stage 2,
where Co, C1, C2 are the solute concentration at feed, stage 1, and 2 respectively, and MT1 , MT2
are the suspension densities at stage 1 and 2, which are calculated from the third moment of the
population density at each stage.
MTI = fk,pLn dL = 6kp nj (G1 i )4 (10)
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M =6k~p n2(G 2 r2 )4 + G (Gr) - (G22 (11)T2 2 2 GI'rl - G21-2 _
where p is the solid density and k, is a volume shape factor.
The crystal growth rate and nucleation rate can be expressed as a function of
supersaturation in the form of empirical power-law equations (8), (9), and (10), where Gi and Bi
are crystal growth rate and nucleation rate at stage i respectively, Ci is the steady state
concentration at stage i, Cisat is the equilibrium concentration at stage i, T is the temperature, R is
the gas constant (8.314 J/mol-K), whereas kg, kgo, kgi, g, kb, and b are model parameters.
G g= kg ' s,' (12)C1
kg = kgo exp ( + (13)
R(T + 273),
B k ' sa(14)
0 B,n , = G , ( 1 5 )
Temperature-dependent solubilities of Aliskiren Hemifumarate in EtOAc/EtOH were measured
by HPLC.
Volume based distribution of the steady state CSD experimental data were converted to
population density data using the relationship
n A MM (16)
ex ALkpL3
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Where nexp is the experimental population density, AM is the mass based CSD (%), MT is the
slurry density, AL is the size range, k, is the volume shape factor, L is the characteristic size of
the crystal and p is the crystal density.
If the error is defined as the difference between the measured (experimental) and calculated
values of the crystal size distribution, then a least-squares optimization procedure to estimate the
kinetic parameters consists of finding the values of 6 that minimize the objective function V/(6)
defined as the sum of squares of the error, where 0 is the vector of model parameters, 0 kgo,
kgi, g, kb, b ]. The optimization problem is expressed as
mm #stagesL max1
1(D() = e, - n(L)y (17)01 0
subject to equations (4) to (10).
Thus, the population balance equations for each stage, as well as the mass balances and
expressions for kinetics of crystallization are solved with initial values for the parameters 0, and
the obtained crystal size distribution for each stage is compared to the experimental data. The
value of the parameters 0 is then recalculated and the procedure is repeated until a minimum
value for the sum of squares of the error is found. Typical assumptions include that the errors of
each measurement are independent and are normally distributed with zero mean.
Once the optimal values for kinetics parameters are found, the crystal growth rates and
nucleation rate at steady state are calculated for each stage, using equations (8), (9), and (10).
The mass based mean size of the crystals can be estimated for each stage i from the third and
fourth moments of the size distribution.
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fL4ndL
( , =(18)f Ln dL
0
Using the population density expressions for each stage (equations (4) to (5)) to solve the
integrals, crystal mean size is obtained as a function of mean residence times, crystal growth rate,
and population density of nuclei for each stage.
L 4 ,3 = 4GIrI (19)
4n2 (G 2r 2 )5 + 4ni I (Gi, ) - (G2r 2 )5
L4,3 = -- j-- (20)
n2o (G2 2)4 + ni G r (Gir )4 - (G2T2)4
2 21) 1Girl - G2r'2 IG
2.7. Spherical Particle Generation
Spherical agglomerates were generated by evaporative crystallization from water-in-oil
emulsions [40]. The lactose or D-mannitol was dissolved in 8 mL of water. The mass of each
compound depended on its respective solubility at 40 0C (0.25 g/mL lactose, 0.46 g/mL for D-
mannitol). The aqueous solution (the dispersed phase) was then added to 72 mL of dodecane
which served as the continuous phase. The mixture was stirred at 650 rpm at 70 0C to obtain a
stable emulsion. The emulsion was stabilized using 1 w/w% surfactant, a mixture of span 20 and
span 80 at a mass ratio of 3 to 7. CTAB was added as an additive to promote nucleation in the
emulsion system. Once the emulsion was stabilized (observed optically), the temperature was
raised to 800C to slowly evaporate the water. Samples were taken and analysed by optical
microscopy every 15 minutes to determine when crystallization was complete. Once
crystallization was observed, the particles were filtered and dried in a vacuum oven.
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2.8. Nucleation Kinetics Measurements
Average nucleation induction time, r, was measured to determine the effect of spherical
morphology on the nucleation rate of AAP. The induction time is the time lag between the onset
of supersaturation and the occurrence of nucleation. - is a useful measure of how much a surface
aids nucleation because the value can be greatly reduced if the surface lowers the kinetic barrier
to nucleation [32]. Due to the stochastic nature of nucleation, a large number of identical
experiments were required in order to obtain a statistically significant result. Several assumptions
were made for this analysis. First, the detection of heterogeneous nucleation was the detection of
secondary nucleation of AAP - it was assumed the time between heterogeneous nucleation and
secondary nucleation occurring was negligible. Second, the time required for the system to reach
the desired supersaturation was assumed negligible in comparison to r. Finally, the growth rate
of acetaminophen was assumed to be much faster than the nucleation rate, such that the time
difference between nucleation and detection could be ignored.
Induction time data were collected using a RS 10 Clarity Solubility Station from Thermo
Fisher Scientific [59]. This method has been used in a number of other studies [33, 34]. A stock
solution of AAP in ethanol was prepared (232.75 g/kg, saturated at 300C). 1.5 mL aliquots were
then syringe filtered into an HPLC vial to remove any solid impurities. The vials were agitated
with a magnetic stir bar rotating at 700 rpm. The samples were then quench cooled to 15C
which resulted in a supersaturation (F) of 1.36. G = c*/ceq, where c* is the actual concentration
and ceq is the equilibrium concentration at a given temperature. For experiments with the
substrates, approximately 3 mg was added into each vial prior to the addition of the AAP/ethanol
solution.
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2.9. EpiCalc Calculations
The interface between a substrate crystal face and an overlayer crystal face is defined by
7 parameters: a,, a2, a (describing the substrate), b1 , b2, p, (describing the overlayer), and $.
These parameters are shown in Figure 1. The parameters (a,, a2) and (b1 , b2) are pairs of vectors
describing the 2-dimensional lattices of a crystal substrate and overlayer, respectively. The
parameters a and p are the angles between each pair of vectors. The variable $ is known as the
azimuthal angle and is defined as the angle between the a, and b, vectors and therefore describes
the orientation of the overlayer with respect to the substrate. The three modes of epitaxy are
commensurism, coincidence, and incommensurism. Commensurism is defined as a total lattice
match between the substrate and overlayer, while coincidence is a partial lattice match.
Incommensurism means that the lattices do not match.
The lattice agreement between the substrate and AAP was determined using EpiCalc
Version 5 [60-62]. This software calculates the lattice agreement between two surfaces using a
dimensionless potential energy, V/VO, as a measure of goodness of fit. The value for VVo ranges
between -0.5 and 1, where a value of 1 indicates incommensurism, 0.5 implies coincidence, 0
indicates commensurism on a non-hexagonal substrate, and -0.5 commensurism on a hexagonal
substrate. The angle $ was varied between 00 and 1800 in intervals of 0.250. The size of the
overlayer was set to 25blx25b2. The output is a plot of the potential V/VO as a function of the
azimuthal angle $.
2.10. Molecular Dynamics Simulations
Systems containing a crystal slab of triclinic lactose or p-mannitol, with dimensions of
approximately 90x90x15 A, and an overlayer of AAP (Form I), with dimensions of
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approximately 50x50x20 A, were constructed with various crystal faces aligned to one another.
The following faces of lactose and AAP were aligned: (140)/(001), (14T)/(001), (20T)/(001),
(011)/(00 1), and (011)/(111). These faces were chosen as representative pairs in the absence of
experimental data showing which faces of lactose and AAP are bound together. The (140), (14T)
and (20T) faces of lactose were chosen because of their increased presence in the spherical
agglomerates (vide infra) whereas the (011) face was chosen because it is the most abundant face
in the single crystal form. The (001) and (111) faces of AAP were chosen because they have
been previously determined to be the fastest growing faces [63]. For D-mannitol and AAP a
previous epitaxy study demonstrated that the (00 T)/(100) are bound together, therefore we
simulated the energy interaction between this pair [35]. Table 2-1 summarizes additional
simulated pairings. These additional face pairings showed neither lattice matching from the
EpiCalc calculations nor favourable energy interactions and will not be discussed in the results
section.
Table 2-1: Face Pairings Between AAP and Lactose and Mannitol Investigated Using Molecular Dynamics Simulations in
the Present Study.
AAP
001 111 100 011
Lactose 14T x
140 x
20T x
11T x x
011 X x
011 x
10T x x
Mannitol 00T x x x
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Each alignment was carried out such that the face-to-face distance between lactose or
mannitol and the AAP overlayer was approximately 3 A. After the initial alignment, the AAP
overlayer was rotated through 2.5 degree increments for 360 degrees to produce 144 starting
structures for each system. Following the rotations, all systems were placed in a period box with
box vectors matching the bjb 2-dimensions of the lactose/mannitol crystal. The b3-direction on the
other hand was ascribed a length of 120 A so that face-to-face interactions of periodic images
would be minimized. The basic system setup and geometric parameters are shown in Figure 2-3.
(P 120A
A AP overlayer
al 3
a2
b1
------ -- --b2 90A
90A Lactose/Mannitol
Figure 2-3: Crystal slabs of lactose and mannitol with overlayers of AAP were simulated using the basic geometries
shown. The potential energy as a function of azimuthal angle (cD) between crystal vectors al and b1 were produced
by averaging energies from short low-temperature molecular dynamics simulations.
The Glycam06 force-field parameters [64] were applied to molecules in the lactose
crystal, whereas the following procedure was used to derive parameters for AAP and D-mannitol:
First, xyz coordinates of AAP and mannitol monomers were taken from the crystal structures of
AAP (Form I) and the P polymorph of D-mannitol. The coordinates of these structures were
relaxed to a local minimum on the potential energy surface (zero-imaginary frequencies) using
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the B3-LYP/6-31G(d) level of theory. The electrostatic potentials (ESP) of the AAP and
mannitol monomers were derived by carrying out a single-point energy calculation on the
resultant structures with the HF/6-3 1G(d) level of theory. The resultant ESPs were fit using the
RESP procedure [65, 66] to derive partial atomic charges in accordance with standard parameter
development of AMBER-style force-fields [67]. The remaining parameters for describing bond,
angle, dihedral and vdW potentials were taken from the generalized amber force-field (GAFF)
[68]. All molecular dynamics simulations were carried out using the GROMACS 4.5.3
molecular dynamics suite of programs [69] by using the porting procedure of Sorin and Pande
[70]. All quantum chemistry calculations were carried out using the Gaussian 03 program
package [71].
7000 steps of steepest descent minimization on all rotamers were carried out to derive
relative interaction energies (AE) as a function of azimuthal angle. The resultant structures were
used as shooting points for 10 short (6 ps) low temperature molecular dynamics simulations.
These simulations were performed in order to overcome local energy barriers without causing
major disruptions of the relative lattice angles between the lactose and mannitol crystals and the
AAP overlayer. The final structures from the MD simulations were optimized for a further 7000
steps of steepest descent minimization and the average potential energy of the 10 optimizations
was taken as the energy for the given lactose/mannitol and AAP rotamer. All molecular
dynamics simulations were coupled to a Berendsen thermostat and semi-isotropic Berendsen
barostat to a target temperature of 100 K and target pressure of 1 bar. The isothermal
compressibility in the z-direction was set to 0.0 bar-' in order to maintain the large face-to-face
separations between periodic images. Electrostatic interactions were calculated with the Ewald
particle mesh method [72] using a real space cutoff of 20 A. Bonds involving hydrogen atoms
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were constrained using the LINCS algorithm [73] and the time integration step was set to 2 fs. A
geometric definition for the existence of a hydrogen bond was used for the hydrogen bond
analysis. The acceptor-donor distance cutoff was set to 3.5 A. The angular acceptor- hydrogen-
donor cutoff was set to 300.
2.11. Composite spherical agglomerate generation
To form the composite spherical particles, the two components were dissolved together in
water with concentrations set such that the template molecule would crystallize first, allowing
the target to nucleate heterogeneously on the crystalline template surface. The concentrations
were set such that the nucleation induction time for the template molecule was always shorter
than that of the target molecule, as verified by experiments conducted on the individual
components alone, in the absence of one another. A schematic of this process can be seen in
Figure 2-4.
Evapoato
a eof water
Crystalti zation Tehplating of
Water of Lactose NaCl by Lactose
containing
Lactose and
NaCJ
Doecne
Figure 2-4: Schematic of composite spherical agglomerate generation. Emulsion of water containing heterosurface
(lactose) and template (NaCl) is placed into dodecane and stirred. Emulsion is heated to evaporate water. The
heterosurface crystallizes first, templating nucleation of the target molecule.
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3. CRYSTALLIZATION OF ALISKIREN BOC-BASE
3.1. Introduction
This chapter describes the first of two continuous crystallization processes that were
developed as part of the bench scale unit for continuous manufacturing. Each of the
crystallizations had its own unique challenges. As an intermediate purification crystallization, the
primary concerns for the crystallization of Aliskiren boc-base were purity and process yield. This
chapter describes the work that went into the process development, including challenges using
synthesized material rather pure starting material and the decisions that were made about where
to add anti-solvent into the process. Additionally, this chapter describes the results of the process
modeling performed on the crystallization system. This combined population and mass balance
model was both fitted and validated using experimental data.
3.2. Process Development
3.2.1. Influence of water on the crystallization process of C1.
The feed solution to the crystallization consisted primarily of Cl and C2 in Ethyl Acetate.
Crystallization experiments using pure ethyl acetate, C1 and C2 to form the starting solution
resulted in a yield of 92% Cl recovered with greater than 98 % purity. Crystallization using feed
material from an actual reaction (as opposed to using pure materials) gave a yield of 62% with
significantly lower purity.
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Figure 3-1: Cl solubility versus water content in the organic phase v
A review of the reaction and workup steps suggested that because of an upstream liquid-
liquid separation step, nearly 5 % water was being entrained in the organic stream. The effect of
water on the solubility of Cl can be seen in Figure 3-1. The presence of water significantly
increased the solubility of CI at all measured temperatures. This was unexpected as Cl has low
solubility in both pure Ethyl Acetate and pure water, but a higher solubility in the mixed solvent.
A secondary solvent screen was undertaken to identify a suitable anti-solvent to improve
the crystallization yield. Heptane was identified as a promising choice for the anti-solvent
system. With the addition of heptane, the solubility of Cl was significantly reduced. From Figure
3-1, it can be seen that the addition of 25% heptane reduced the solubility of Cl at all water
content levels. At 3.5 % water, adding 25% heptane reduced the solubility of C1 to below 0.9%,
compared to around 2.5% for the. solution without heptane. The solubility of Cl became stable
with respect to increasing heptane content at 25% heptane solvent content. In consideration of
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the working volume increase and the C1 concentration decrease with the addition of heptane, the
heptane content was set at 25 (m/m) % of the total solvent.
Based on the above results, we employed a continuous anti-solvent + cooling procedure for
the C1 crystallization with the temperature of the first crystallizer set at -5 *C and the second
stage, was set at -10 *C.
3.2.2. Influence of anti-solvent on crystal properties.
To investigate the influence of anti-solvent on crystal properties, X-ray diffraction patterns of
C1 crystallized with varying heptane concentrations were measured and the results are shown in
the Figure 3-2. As the concentration of the anti-solvent was increased, the level of
supersaturation also increased. The supersaturation increase lead to a higher nucleation rate and
thus more fines and amorphous material in the final product. These are identified by peak
broadening and a raised baseline of the diffraction patterns. From optical microscope picture as
shown in Figure 3-3, it can be seen there are some large agglomerates in the crystals generated
using 25 % anti-solvent.
25% Heptane
10% Heptane
50% Heptane
No Heptane
0 5 10 15 20 25 30 35 40 45
2Theta, degree
Figure 3-2: X-ray diffraction of C1 crystallized in EtOAc with different heptane content
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Figure 3-3: Microscope images of C1 crystallized in batch with 25% heptane
During the process development, it was not initially clear whether adding the anti-solvent
in the first or the second vessel was a better option due to the unknown kinetic information. To
answer which option will be better, the effect of the anti-solvent addition on the crystal
properties was determined.
First stage
Second stage
0 5 10 15 20 25 30 35 40 45
2Theta, Degree
Figure 3-4: XRPD of Cl crystallized with anti-solvent feeding at the first stage
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Stage Stage 2
Figure 3-5: Microscope images of C1 with anti-solvent feeding at the first stage
The XRD patterns and optical microscope pictures for crystals generated with anti-
solvent feeding in the first stage can be seen in Figure 3-4 and 3-5, respectively. Figures 3-6 and
3-7 contain XRD and optical microscope pictures for crystals generated with anti-solvent added
into the second vessel.
0
Figure 3-6: XRPD of
10 20 30 40
2Theta, degree
C2 crystallized with anti-solvent feeding at the second stage
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Figure 3-7: Microscope images of CI with anti-solvent feeding at the second stage
0
-2
-4
-6
CU
c) -10
-12
-14
-16
20 40 60 80 100 120 140 160 180 200
Temperature, 0C
Figure 3-8: Comparison of DSC curves of the final products of C1 crystallization
The crystals generated with anti-solvent feeding at the second stage have better
crystallinity compared to those generated with anti-solvent feeding at the first stage. Comparing
the X-ray patterns in Figures 3-4 and 3-6, the crystals from the continuous process with anti-
solvent feeding at the second stage have a much stronger baseline with much sharper and
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Adding anti-sovent in 1st Vessel
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narrower peaks. DSC curves shown in Figure 3-8 help demonstrate this crystallinity result. As
shown in the DSC curves, for the product generated by adding anti-solvent in second stage, the
melting peak is sharper and narrower and thus more crystalline. By adding anti-solvent in the
second stage, the supersaturation in the first stage vessel is significantly decreased, and the entire
process was operated at lower supersaturation level. From the optical microscope pictures, the
crystals generated with anti-solvent added in the first vessel are much more agglomerated.
Crystals generated with anti-solvent added to the second vessel are more suitable for downstream
processing because they allow for an easier downstream filtration step.
3.2.3. Evolution of continuous crystallization process.
The temperature, yield of crystallization and the CLD of the crystals in the two stages
were tracked over the duration of crystallization process to monitor the process state to confirm
that steady state was reached. As shown in Figure 3-9, the temperature in each stabilized after 1-
2 residence times. Initially, no temperature was recorded until the level of slurry reached the
temperature probes.
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-6
2 -8
-10 -
-12 -
-14
I I I I | I I I
0 5 10 15 20 25 30 35
Time of crystallization duration, h
Figure 3-9: Temperature versus time in the two stages
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The concentration of Cl in the mother liquor and the CLD of both of the two stages were
tracked over the duration of the crystallization process. As shown in Figure 3-10, the yield
stabilized after 3 residence times. From Figures 3-11 and 3-12, the CLD also stabilized after 3
residence times. As shown in those figures, after 3-4 residence times, the variables monitored
were consistent, and indicate that the steady state was reached.
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Figure 3-10: Yield evolution in the two stages during crystallization startup
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Figure 3-11: CLD evolution in first stage
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To determine if there was significant classification in the crystallizers, samples were
taken at different locations in second stage, including the top of the crystallizer, the bulk slurry
and the bottom of the crystallizer. No significant difference was observed as shown in the
microscope images in Figure 3-13.
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Figure 3-13: Microscope images of the crystals at different locations in 2nd vessel
3.3. Modeling results
3.3.1. Experiments to Determine Distribution Coefficients.
Distribution coefficients for C1 impurities were calculated by applying equation 1 to data
obtained experimentally. A plot of the Distribution Coefficient as a function of the purity of the
initial solution is shown in Figure 3-14. This information was then used to model the continuous
crystallization process and determine the effect of process conditions on purity and yield. A plot
of the Distribution Coefficient as a function of the purity of the initial solution is shown in Figure
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3-14. This information was then used to model the continuous crystallization process and
determine the effect of process conditions on purity and yield.
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Figure 3-14: Distribution Coefficients as a function of purity of the starting solution
The variation of the distribution coefficient can be attributed to a couple of reasons.
Firstly, the current crystallization process is a combined cooling-anti-solvent process. In Figure
3-14, the distribution coefficient incorporates the cooling and anti-solvent process, and there is a
big variation for the distribution coefficient over the impurity level between the two procedures.
And it is the main reason for the variation of the distribution coefficient in Figure 3-14.
Secondly, during the experimental process, we gave same reaction time for each step to achieve
equilibrium. However, there are still some deviation between the experimental state and the
equilibrium state. So, it is possible that some points in Figure 3-14 showed a big deviation.
Finally, the different mixing profiles and working volume can be considered to generate the
experimental errors.
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3.3.2. Mathematical model of cascaded multistage crystallization system.
As described in Chapter 2.7, the MSMPR model can be used to estimate the nucleation
and crystal growth rate kinetic parameters by solving the optimization problem defined in
equation 17. This approach was used to obtain kinetics from the continuous crystallization
experiment of C1 in EtOAc-heptane. Process parameters for the experiments can be seen in
Table 3-1.
Table 3-2 shows the volume based mean crystal size obtained in stages 1 and 2 as well as
the supersaturation in each stage. It was observed that the mean size of C1 crystals in the each
stage was not significantly different. This is because the anti-solvent was introduced in the
second stage, and thus the supersaturation was kept at similar level in both stages. At the same
time, a high supersaturation level in stage one was avoided and the nucleation rate and the crystal
growth rate in both of the two stages were kept at the suitable level in the entire process, and the
final product with higher crystallinity and better crystal morphology were generated (see Figure
3-6 & 3-7).
Table 3-1: Process conditions for estimation
Condition
Volume Stage 1, V1
Volume Stage 2, V2
Flowrate Stage 1, Q1
Flowrate Stage 2, Q2
Temperature Stage 1, TI
Temperature Stage 2, 72
Solubility at TI
Solubility at 12
Concentration of API, CO
Density of Crystal
Density of Solvent
Density of Anti-solvent
of nucleation and crystal growth kinetics
Value Units
30 mL
41 mL
0.125 mL/min
0.174 mL/min
-5 C
-10 C
0.0318 Kg/Kg
0.0089 Kg/Kg
95.2 Kg/m3
1200 Kg/m3
897 Kg/m 3
684 Kg/m 3
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Table 3-2: Mean crystal size (volume based) in stage 1 and 2
Temperature(fC) Residence time (min) Supersaturation
-5 240 0.35
-10 240 0.29
Mean Size (pm)
71.69
71.77
The results from the two stages were included in the optimization, and the difference
between calculated and experimental crystal size distribution was minimized. To obtain an
efficient optimization and accelerate convergence, the parameters kgo, kgi, and kb were scaled
nonlinearly, using ln(kgo), ln(kgi), and ln(kb) respectively. The results of the parameter estimation
are shown in Table 3-3. A comparison between the calculated and experimental chord length
distributions can be seen in Figure 3-15.
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Figure 3-15: Predicted and experimental CLD for C1 continuous crystallization
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Table 3-3: Estimated nucleation and crystal growth kinetic parameters
Parameter Value Units
kg@ -5 -C 2.33 x 10-' r/m
kg@ -10 -C 9.86 x 10-8  r/min
kgo 9.81 x 1012 m/min
kgi 12116 J/mol
kb 6.92 x 10" #/m 3 min
g 1.09 Dimensionless
b 3.99 Dimensionless
In order to test the validity of the model, the experiments were re-run with different
parameters. The previously calculated parameters were then used to simulate the effects of
changing these experimental parameters, and the results were then compared. The temperature of
the first stage was changed to 00C, and samples were taken in the two stages at steady state to
measure the CLD by FBRM. As shown in Figure 3-16, the model results agree reasonably with
the experimental size distribution. Linear kinetic order for crystal growth and quadratic kinetic
order for nucleation are both physically realistic results. The differences between the model and
the experimental data can be explained in part by the fact that Cl crystals have a needle-like
morphology (Figure 3-7). One assumption of the model is that the crystals have perfectly
spherical morphology, and this difference is known to impact on the accuracy of the model [57,
58, 74]. With a needle like morphology the needle width has a greater probability than the needle
length of being measured by the scanning laser. For the FBRM chord length distributions, an
increase in number of small chord lengths does not necessarily imply secondary nucleation, but
can also be indicative of crystal growth. An increase in needle length will lead to an increase in
small chord lengths counted over time.
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Figure 3-16: Predicted and experimental CLD for C1 continuous crystallization for model validation
In addition to the spherical crystal assumption, there are a number of other assumptions
involved in the population balance equation which will give rise to differences between the
experimental and predicted crystal size distributions. It is assumed that the product CLD is the
same as that found within the crystallizer, i.e. there is no classification of the particles in the
crystallizer takes place. This is the standard assumption used in reaction engineering to define a
well-mixed reaction vessel. This might not be the case if there is imperfect mixing or dead zones
in the vessel. Secondly, it is assumed that particles are formed only by nucleation and increase in
size only through growth and that the processes of breakage, attrition, and agglomeration are
negligible. In the real system, agglomeration and the breakage of the crystals are inevitable and
can be a significant factor especially for systems with needle morphology. Finally, because the
crystals are needles, the assumption that shape factors for particles are not a function of size may
not be completely accurate. Unlike spheres, a needle cannot be described with a single
characteristic size, unless the aspect ratios for all needles are equivalent. Breakdowns in these
assumptions provide additional deviations when comparing the model with the experimental
data.
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3.3.3. Effect of Process Conditions on Crystal Purity and Yield.
The multistage MSMPR model was used to evaluate the effect of operating conditions on
the purity of the crystal and the process yield in the continuous crystallization process of C1. The
influence of the temperature and residence time of both of the two stages on the crystal purity
and the process yield are evaluated. The effect of the temperature of each stage on the product
yield purity can be seen in Figure 3-17. For comparison, in the batch experiments at -5'C, and
-10'C, the purity of the crystals was 89.60% and 88.48%, respectively.
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Figure 3-17: Effect of temperature of stage 1 & 2 on process yield
Changing the temperature of each stage has a significant effect on the process yield. By
varying the temperature by 15"C from the actual chosen operating temperatures, the yield
decreased from 89.8% to 85.7%. This is because the solubility of Cl increases with increasing
temperature. Increasing the temperature even further would decrease the yield even more.
The effect of the temperature of each stage on the final crystal purity was also studied, and the
results can be seen in Figure 3-18.
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Figure 3-18: Effect of temperature of stage 1 & 2 on crystal purity
The results indicate that changing the temperatures of the stages results in a maximum
purity difference of 0.7%. That is because the entire process included anti-solvent crystallization
process and cooling process, and the influence of only temperature as shown here is not so
significant. As the temperature in second stage increases, the purity of the crystals also increases.
This is due to the fact that, at steady state, the concentration of the impurities in the liquid phase
in second stage is reaching a higher level when the temperature is lower. The results from Figure
18 and Figure 19 show that the temperatures at both of the two stages have opposite effects on
purity and process yield. As process yield is increased, product purity decreases.
The influence of the residence time on the yield and purity of the final product were also
evaluated as well and the results are shown in Figures 3-19 and 3-20. The residence time of each
stage was varied between 120-800 minutes. The product yield varied from 87.5% to 91.0%. The
kinetics of crystal growth for Cl are quite slow, so it takes a very long time for the concentration
to reach the solubility limit. Not surprisingly, when the second stage had a very long residence
time, the residence time of the first vessel did not affect the product yield significantly. For the
product purity, the crystal purity decreased with increasing residence time. Increasing the
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residence time of the first vessel showed a greater effect on the purity than decreasing the
residence time of the second vessel. The product purity ranged from 91.0% to 91.6%. Again,
there was a negative correlation between product purity and yield when changing the residence
time.
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Figure 3-19: Effect of residence time of stage 1 & 2 on crystal purity
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Figure 3-20: Effect of residence time of stage 1 & 2 on process yield
The relationship between the purity of the final product and the process yield has been
correlated and it can be clearly seen that the opposite influence of process parameters on the
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purity and yield. This behavior is shown in Figure 3-21. The model was used to evaluate the
effect of process parameters on the purity of the crystals and the process yield. The results of the
model could be used to find out the optimal operating conditions to maximize yield without
having too high impurity content.
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Figure 3-21: Purity of the crystals as a function of process yield
Attributed to the growing interest in the development of continuous crystallization
processes in the pharmaceutical industry, it has been an urgent requirement to develop robust
continuous crystallization processes which produce API crystals with high yield and purity.
While batch manufacturing process is still preferred in the current pharmaceutical industry, the
development of continuous systems such as the one described in this paper will help the industry
in moving from batch to continuous manufacturing.
3.4. Conclusions
A multistage cascaded MSMPR continuous crystallization system was optimized for the
continuous crystallization of Aliskiren boc-base using cooling and anti-solvent to generate
supersaturation. Its capability to crystallize an organic compound was experimentally
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demonstrated. XRPD results indicate that the vessel in which anti-solvent is added has a
significant influence on the final crystal properties. Adding anti-solvent in the second vessel
resulted in crystals with increased crystallinity and better morphology for downstream
processing. Focused Beam Reflectance Measurement (FBRM) technology was employed to
track the crystals size distribution of Aliskiren boc-base. A mathematical model was used to
analyze the experimental results. By combining the process model with an optimization
algorithm, the nucleation and growth rate parameters were extracted and used to predict the size
distribution under different process conditions. The multistage MSMPR model was used to
evaluate the effect of process conditions, including the temperature and residence time, on the
purity of the crystal and the process yield in the continuous crystallization process of Aliskiren
boc-base.
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4. CRYSTALLIZATION OF ALISKIREN HEMIFUMARATE
4.1. Introduction
Chapter 4 describes the second of the continuous crystallization steps developed for the
bench scale continuous manufacturing platform. Unlike the crystallization for Aliskiren boc-base
which was an anti-solvent and cooling crystallization, the crystallization of Aliskiren
hemifumarate is a simultaneous reaction and crystallization step. Due to the solubility and
filtration behavior, a number of different solvent combinations and operating temperatures were
iterated before the final operating conditions were found. This system was also modeled using
the distribution coefficient model and the population and mass balance equations defined in
Chapters 2.5 and 2.6.
4.2. Process development
Fumaric acid is nearly insoluble in ethyl acetate. Because of this, ethanol was added to
solubilize the acid. Adding ethanol to the ethyl acetate stream, however, increased the solubility
of Aliskiren, as can be seen in Figure 4-1. The higher final solubility results in an overall lower
yield, so great care was taken to avoid adding more ethanol than necessary. Fumaric acid
solubility in ethanol at 70'C is approximately 11 w/w%, so this was chosen as the starting
point[75]. Because 70'C is close to the boiling point of ethanol, in order to avoid evaporating too
much of the solvent, the ethanol was diluted with an equal mass of ethyl acetate. Experiments
showed that the solubility of fumaric acid on a per mass of ethanol basis increased slightly after
adding ethyl acetate, so there were no concerns about the fumaric acid precipitating out.
Preventing the evaporation of the ethanol was also important because the ratio of fumaric acid to
Aliskiren freebase is paramount to the success of the crystallization. If the ratio is too low, then
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the resulting product would be a mixture of the freebase and the hemifumarate form. If the ratio
is too high, then the yield of the process is significantly decreased, with ratios of 0.75 or greater
resulting in nearly no crystals. This is likely due to the formation of a fumarate salt in solution,
though this was not experimentally determined.
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Figure 4-1: Solubility of C3 as a function of ethanol solvent content
The next design step was to choose the temperatures of the two stages. The solubility of
Aliskiren Hemifumarate as a function of temperature can be seen in Figure 4-2. As expected, the
lower the temperature, the lower the solubility. To maximize yield, the temperature of the two
stages should be as low as possible, but there were other circumstances to consider. Because the
reaction takes place in solution in the first stage, it was decided that the temperature of that stage
should be higher to avoid overly rapid supersaturation generation. In addition, if the temperature
was too low, the fumaric acid could precipitate faster than it reacted with the free base, which
would prevent the formation reaction of the hemifumarate. Thus, an operating temperature of 20 0C
was chosen. For the second vessel, to maximize the yield of the process, an operating
temperature of -10*C was chosen. This temperature was low enough to maximize yield without
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going beyond the capacity of the refrigerated circulators and without decreasing the growth rate
of the crystals too much.
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Figure 4-2: Solubility of C3 at 95/5 (w/w%) ethyl acetate/ethanol solvent composition
4.3. Technical Challenges and crystallization results
The operation of this crystallization had some significant technical difficulties. Because
of the scale of the crystallizations, the slurry flow rates between the vessels were very low. Had
the pumps been set to pump continuously, the flow rate would have been 0.17 mL/min. To
achieve that flow rate, the tubing between the vessels would have to be very small, and this
would cause issues with clogging. In addition, the low flow rate would cause issues with settling
of the solids in the pump lines. In order to mitigate this issue, the pumps were turned on at set
intervals of time at very high flow rates. In this way, the slurry was moved very quickly between
vessels, avoiding issues with settling. Also, wider tubing was used to avoid issues with clogging
of the lines. The pumps were set to operate once every 20 minutes, such that less than 10% of the
contents of each stage were transferred in each step. Another technical issue involved the
pumping of the fumaric acid. Because the concentration of the fumaric acid in the solution was
close to saturation at 70*C, as the solution was transferred to the first stage of the crystallization,
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the line would often become clogged. This was primarily because the fumaric acid solution
decreased in temperature inside of the tubing and thus the fumaric acid precipitated
uncontrollably. To solve this problem, the transfer lines were changed to metal tubing, with only
a small section of plastic tubing inside of the peristaltic pump head. In addition, the metal tubing
was covered with heating tape heated to 70'C in order to maintain the temperature.
The continuous crystallization system was run for 48 hours, with samples taken
intermittently to check for steady state. In typical experiments, the concentration of the mother
liquor after the first stage was approximately 1 w/w% Aliskiren. After the second stage, the
mother liquor concentration was approximately 0.5%. Both of these values are very close to the
equilibrium values, and matched closely with batch experiments. At typical loadings of 6.5%,
these mother liquor concentrations would result in yields of 85% and 92.3% in the first and
second stages, respectively. Recycles could be used to increase this yield if it was deemed too
low. After filtration, the mother liquor could be concentrated by evaporating some of the solvent,
and this concentrated stream could be sent back to one of the stages for further crystallization.
Investigations of recycle streams are beyond the scope of this work.
An optical microscope picture of Aliskiren Hemifumarate crystals produced using the
previously described continuous crystallization method can be seen in Figure 5. The crystals
have needle-like morphology with a length of around 50 micrometers. Crystals produced in batch
using the same solvent composition and final operating conditions (stirring rate, temperature etc.)
were of a similar size. Thus, the continuous crystallization produced crystals with very similar
physical properties. In Figure 4-3, an XRPD pattern of the final crystallized product can be seen.
The crystals exhibit some sharp peaks, but lack a strong baseline, indicating some amorphous
content.
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Figure 4-3: Optical Microscope picture of crystallized Aliskiren Hemifumarate
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Figure 4-4: XRD pattern of crystallized product
4.4. Modeling results
4.4.1. Experiments to determine equilibrium Distribution Coefficients
Distribution coefficients for C3 impurities were calculated by applying equation 1 to data
obtained experimentally. A plot of the Distribution Coefficient as a function of the purity of the
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initial solution is shown in Figure 4-5. This information was then used to model the continuous
crystallization process and determine the effect of process conditions on purity and yield.
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Figure 4-5: Distribution coefficients for Aliskiren Hemifumarate
4.4.2. Mathematical Modeling and Parameter Fitting
As described in the previous section, the MSMPR model can be used to estimate the
nucleation and crystal growth rate kinetic parameters by solving the optimization problem
defined in equation 17. This approach was used to obtain kinetics from continuous crystallization
experiments of Aliskiren in EtOAc-EtOH. Process parameters for the experiments can be seen in
Table 4-1.
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Table 4-1: Process conditions for estimation of nucleation and growth parameters
Condition Value Units
Volume Stage 1, V1  30 mL
Volume Stage 2, V2  30 mL
Total Flowrate, Q 0.125 mL/min
Temperature Stage 1, T1  25 C
Temperature Stage 2, T2  -10 C
Solubility at T1  0.009 Kg/Kg
Solubility at T2  0.001 Kg/Kg
Concentration of API, CO 63.9 Kg/m 3
Density of Crystal 1200 Kg/m3
Density of Solvent 891.6 Kg/m3
The model is built based on the population balance, which is based on the concept of
continuous mixed-suspension, mixed product-removal (MSMPR) crystallizers developed by
Randolph and Larson (1971) and its power of the population balance for analysis of crystallizers
is demonstrated by its application to a continuous crystallizer [17, 18, 21]. The results from the
two stages were included in the optimization, and the difference between calculated and
experimental crystal size distribution was minimized. To obtain an efficient optimization and
accelerate convergence, the parameters kgo, kgi, and kb were scaled nonlinearly, using ln(kgo),
ln(kgi), and ln(kb) respectively. The results of the parameter estimation are shown in Table 4-2,
and a comparison between the calculated and experimental crystal size distributions can be seen
in Figure 4-6.
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Table 4-2: Estimated nucleation and growth parameters
Parameter Value Units
kg @ 250 C 1.55 x 108  m/min
kg@ -100C 4.17 x 10-9  i/mn
kgo 0.00029 m/min
kgi 2935 J/mol
kb 3.2 x 107  #/m 3 min
g 1.08 Dimensionless
b 1.95 Dimensionless
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Figure 4-6: Fitted chord length distributions for vessels 1 (left) and 2 (right)
FBRM was employed to obtain the experimental crystal size distribution. As shown in
Figure 4-6, the model results agree very well with the experimental size distribution. The small
differences between the model and the experimental data can be explained in part by the fact that
Aliskiren crystals have a needle-like morphology (Figure 5). One assumption of the model is that
the crystals have perfectly spherical morphology, and this difference is known to impact on the
accuracy of the model [8, 57]. Because the crystals were assumed to be spheres, a single
characteristic size was used as a measure of the size of the particles [74]. With a needle like
morphology the needle width has a greater probability than the needle length of being measured
by the scanning laser. For the FBRM chord length distributions, an increase in number of small
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chord lengths does not necessarily imply secondary nucleation, but can also be indicative of
crystal growth. An increase in needle length will lead to an increase in small chord lengths
counted over time.
In addition to the spherical crystal assumption, there are a number of other assumptions
involved in the population balance equation which will give rise to differences between the
experimental and predicted crystal size distributions. It is assumed that the product CLD is the
same as that found within the crystallizer, neglecting classification of the particles in the
crystallizer. This is the standard assumption used in reaction engineering to define a well,mixed
reaction vessel. This might not be the case if there is imperfect mixing or dead zones in the
vessel. Secondly, it is assumed that particles are formed only by nucleation and increase in size
only through growth and that the processes of breakage, attrition, and agglomeration are
negligible. In the real system, agglomeration and the breakage of the crystals are inevitable and
can be a significant factor especially for systems with needle morphology. Finally, because the
crystals are needles, the assumption that shape factors for particles are not a function of size may
not be completely accurate. Unlike spheres, a needle cannot be described with a single
characteristic size, unless the aspect ratios for all needles are equivalent. Breakdowns in these
assumptions provide additional deviations when comparing the model with the experimental data.
4.4.3. Effect of Process Conditions on Crystal Purity and Yield.
The multistage MSMPR model was used to evaluate the effect of operating conditions on
the purity of the crystal and the process yield in the continuous crystallization process of
Aliskiren Hemifumarate. The influence of the temperature and residence time of both of the two
stages on the crystal purity and the process yield are evaluated. The effect of the temperature of
each stage on the product purity can be seen in Figure 4-7.
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Figure 4-7: Effect of temperature of stage 1 and 2 on crystal purity
Changing the temperature of each stage has a moderate effect on the crystal purity. By
varying the temperature of each stage by 15 degrees from the actual selected operating
temperatures, the purity decreased from 99.8% down to 98.4%. This is because the solubility of
Aliskiren Hemifumarate increases with increasing temperature. Increasing the temperature even
further would decrease the yield even more.
The effect of the temperature of each stage on the final process yield was also studied,
and the results can be seen in Figure 4-8.
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Figure 4-8: Effect of temperature of stage 1 and 2 on process yield
The results indicate that changing the temperature of the stages has a great influence on
the process yield. Changing the temperature of each stage by 15*C resulted in a yield range from
90% down to nearly 40%. Even though the crystallization is a reactive crystallization, the final
salt is still fairly soluble in the solvent system at moderate temperatures. The results from Figure
9 and Figure 10 show that the temperatures at both of the two stages have opposite effects on
purity and process yield. As process yield is increased, product purity decreases.
The influence of the residence time on the yield and purity of the final product were also
evaluated as well and the results are shown in Figures 4-9 and 4-10. The residence time of each
stage was varied between 120 and 600 minutes. The final crystal purity varied from 97.6% at the
longest residence times to 99.6% at the shortest residence times.
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Figure 4-9: Effect of residence time of stages 1 and 2 on crystal purity
The product yield ranged from 71% at the shortest residence times to 93.6% at the
longest residence times. Increasing the residence time of the first vessel increased the product
yield more significantly than changing the residence time of the second vessel. At a residence
time of 120 min in vessel 1 and 600 min in vessel 2, the yield was only 81.2%, but with a
residence time of 600 min in in vessel 1 and 120 min in vessel 2, the yield was 90.8%. Because
Aliskiren Hemifumarate is a slow growing molecule, the effects of having a higher temperature
on the growth rate are magnified. Because vessel 1 was operated at a much higher temperature, it
is logical that the increased temperature and residence time in vessel one would result in a higher
final yield than the same residence time in the much colder second vessel. Again, there was a
negative correlation between product purity and yield when changing the residence time.
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Figure 4-10: Effect of residence time of stages 1 and 2 on process yield
The relationship between the purity of the final product and the process yield has been
correlated and it can be clearly seen that the opposite influence of process parameters on the
purity and yield. This behavior is shown in Figure 4-11. The results of the model could be used
to find out the optimal operating conditions to maximize yield without having too high impurity
content.
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Figure 4-11: Purity of crystals as a function of process yield
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4.5. Conclusions
A multistage cascaded MSMPR continuous crystallization system was optimized for the
continuous reactive crystallization of Aliskiren Hemifumarate using cooling to generate
supersaturation. The process to produce crystals at both high yield (>92%) and purity (99%).
with good crystal morphology was demonstrated. Though increasing the process yield results in
a less pure crystal, even at 94% yield, the A number of technical challenges rising from working
at such a small scale were solved. Focus Beam Reflectance Measurement (FBRM) technology
was employed to track the crystals size distribution of Aliskiren Hemifumarate crystals. A
mathematical model was used to analyze the experimental results. By combining the process
model with an optimization algorithm, the nucleation and growth rate parameters were extracted.
The multistage MSMPR model was then used to evaluate the effect of process conditions -
temperature and residence time - on the purity of the final crystals and the process yield. The
results showed that the crystal purity and process yield had a monotonic relationship, wherein as
one increased, the other decreased. This crystallization process is now ready to integrate into the
end-to-end continuous manufacturing demonstration unit.
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5. TEMPLATED NUCLEATION ON SPHERICAL AGGLOMERATES
5.1. Introduction
Chapter 5 is the first of two chapters to describe new experimental techniques using
spherical agglomerates made through evaporative water-in-oil crystallization. In this chapter,
induction time measurements for the crystallization of acetaminophen in the presence of single
crystal and spherical lactose and mannitol are shown. The significant difference in induction time
between the single crystal and lactose cases will be explained through the significant differences
in crystal morphology. An in-depth look at the epitaxy between the acetaminophen and the
lactose will reveal coincident lattice matches between the fastest growing faces of
acetaminophen and one of the new faces of lactose that is present in the spherical agglomerate
that is not present in the single crystal lactose. Additionally, molecular dynamics simulations
further show that the interactions between the new faces of lactose and the fastest growing faces
of acetaminophen are highly energetically favorable.
5.2. Generation of Spherical Agglomerates
Spherical agglomerates of triclinic lactose and the p polymorph of D-mannitol were
generated using the method outlined in the experimental section. Optical micrographs and SEM
images of spherical agglomerates of lactose crystals can be seen in Figure 5-1. The agglomerates
were filtered after crystallization and analyzed using SEM. The agglomerates were composed of
many single crystals. The individual crystals making up the agglomerates were small (<1
microns). The crystal form of lactose comprising the spherical agglomerates was found to be the
triclinic polymorph.
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Figure 5-1: Optical microscopy image (left) and SEM image (right) of Triclinic Lactose Spherical Agglomerates.
Individual crystals comprising the spherical agglomerates are on the nanometer scale in length
Figure 5-2 shows optical micrographs and SEM images of spherical D-mannitol
agglomerates. The optical micrograph shows there is little bulk nucleation, and that the mannitol
crystallized as spherical agglomerates with diameters between 5 - 30 Im. This can be seen in
greater detail in the SEM image. The p polymorph crystallized, as will be shown in XRPD data
to be discussed later. The individual crystals comprising the spherical agglomerates were very
small, some on the scale of hundreds of nanometres.
Figure 5-2: Optical microscope image (left) and SEM image (right) of p-Mannitol Spherical Agglomerates. Crystals
comprising the spherical agglomerates are on the order of nanometers in length.
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Image analysis was used to determine changes to the surface morphology of the
substrates due to crystallizing them as spherical agglomerates. Figure 5-3 shows SEM images of
single crystals of triclinic lactose and (p)-D-mannitol. The single crystals of lactose were long
thin plates between 5 and 30 microns in length. From comparing the lactose particles in Figures
5-1 and 5-3, it is evident that the lactose crystals in the spherical agglomerates were
morphologically different from those in the single crystal sample. For D-mannitol, the single
crystals in Figure 5-3 range from 20 microns to 200 microns in length (for the long axis), much
larger than the diameter of the spherical agglomerates. The morphology of the mannitol crystals
in each image is different. Each system was analyzed using XRPD to study the morphological
differences in more detail.
Figure 5-3: SEM image of single crystals of triclinic lactose (left) and beta mannitol (right). Morphology of the lactose is
significantly different than that of the single crystals comprising the spherical agglomerates. Single crystals of mannitol
are often large
X-ray powder diffraction characterization
XRPD measurements of the single crystal and spherical forms of each substrate were
taken. Figure 5-4 shows the measured powder patterns for single crystal mannitol, spherically
agglomerated mannitol, and the calculated powder pattern for the P polymorph (REF code
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DMANTL07) of mannitol. The single crystal and agglomerated D-mannitol are the P polymorph.
The agglomerated D-mannitol had nearly identical diffraction peaks in terms of location and
intensity as the single crystals, even though the morphology of the D-mannitol crystals changed
significantly. There was one unique peak at 9.7', which was not present in either the XRPD data
of single crystal D-mannitol or the calculated pattern for the p polymorph. This peak does not
correspond to any other known polymorphs of D-mannitol. It is possible this is due to an
undiscovered polymorph, but more likely due to an amount of solid impurity.
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Figure 5-4: XRPD data for Mannitol. The diffraction patterns for the spherical and powder D-mannitol are nearly
identical and match up almost perfectly with the calculated powder pattern for beta mannitol
X-ray powder diffraction data for lactose are shown in Figure 5-5. Single crystal and
agglomerated lactose data are shown along with the calculated powder pattern for triclinic
lactose (REF code EYOCUQO1) for comparison. Though both the single crystal and
agglomerated lactose are the triclinic polymorph, the diffraction patterns have important
differences. Peaks were present in the spherical agglomerate powder pattern that did not
correspond to peaks in the measured pattern of powder triclinic lactose, but were found in the
calculated powder pattern of triclinic lactose. The miller indices of the faces represented by these
peaks were assigned by finding the equivalent peaks in the calculated powder pattern. The four
75
most intense new peaks were identified as the (031), (20T), (140), and (14T) crystal planes.
Unlike for D-mannitol, the change of morphology in the lactose crystals comprising the spherical
agglomerates led to the formation of new crystal faces. For the new peaks of lactose we were not
able to explicitly ascribe any of them as originating from the surface of the agglomerates.
However, the experimental and computational analysis described below is indicative that the
(14T) plane is exposed on the surface.
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Figure 5-5: XRPD data for Lactose. Diffraction patterns for the spherical and powder lactose have some significant
differences. Additional peaks in spherical lactose correspond to peaks in the triclinic lactose calculated powder pattern
5.3. Nucleation Induction Time
The effect of the modified substrate morphology on the nucleation induction time for
AAP from ethanol at a a of 1.36 was studied following the X-ray analysis. The induction time t
was measured without using a substrate and using both single crystal and spherically
agglomerated triclinic lactose and D-Mannitol. We hypothesized the presence of different crystal
faces in the spherical agglomerates of lactose may change the nucleation kinetics of Form I AAP
through a change in the heterogeneous nucleation mechanism. Because no change in the
available crystal faces of D-mannitol was observed for the spherical agglomerates, we predicted
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that no statistically significant change in nucleation kinetics would be observed. T was calculated
using the following statistical analysis. It was assumed that the nucleation induction time
followed a Poisson distribution [33, 76-78]. If k represents the number of expected occurrences
of some event in a time interval, then the probability of k occurrences is
f(X, k) =(1 k !
By setting k = 0 and k = t / c, then the probability that no nucleation event will occur (P) within a
given time t is given by:
P = exp (-T) (2)
-t
In(P) =- (3)
T
Figure 5-6 is a plot of ln(P) versus t, i.e. the probability that a crystallization event has
not occurred after t minutes. Linear regression was performed on the data plotted in Figure 5-6
such that the induction time (r) and associated error could be determined from equation (3).
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Figure 5-6: Plot of the log of the probability that an AAP crystallization event would not occur plotted versus time.
Crystallizations of AAP in presence of spherical lactose show significantly faster kinetics than crystallizations in presence
of powder lactose, while crystallizations in presence of spherical and powder mannitol show similar kinetics
The values of t for each experiment are presented in Table 5-1. AAP nucleation from the
bulk resulted in T = 1020 minutes. r in the presence of single crystal D-mannitol was - 130
minutes, and for the spherical agglomerates - 140 minutes, nearly identical within experimental
and calculated error. For lactose, nucleation induction time of Form I AAP in the presence of
spherical agglomerates showed a greater decrease in 'r compared to that when using single
crystals. The induction time decreased from 840 minutes for single crystals of lactose to 73
minutes for the spherical agglomerates.
Table 5-1: Nucleation induction time (in minutes) for AAP crystallizations. Induction time for spherical triclinic lactose is
1Ix faster than for powder lactose. Induction times for powder and spherical mannitol are approximately the same
D-mannitol Triclinic lactose
Homogeneous
Powder Spherical Powder Spherical
1020+13 130+7 140+2 843+14 73+6
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These results support the hypothesis that the presence of new crystal faces has a greater influence
on nucleation kinetics than a change in the aspect ratio of existing crystal faces. However, there
are additional factors that may contribute to the decrease or lack thereof in the induction time of
AAP. One contribution to the surface morphology is the available surface area per unit mass of
the substrates. Attempts were made to measure the surface area using BET, but were not
successful. The purging step of the BET measurements consistently failed, preventing the
analysis of the samples. Analyses using coarse approximations of the relative surface areas from
the images given in Figures 5-1, 5-2, and 5-3 were inconclusive.
5.4. Epitaxy Study with EpiCalc
In a previous study on the nature of the epitaxy between two surfaces, single crystals of
AAP were grown on the surface of single crystals of a-lactose monohydrate to determine which
crystal faces were bound together by single crystal X-ray diffraction [35]. The bound faces were
used in determining the presence or absence of lattice matching. In this study, it was not possible
to determine which crystal faces were involved in the epitaxy. The spherical agglomerates were
relatively small (10-50 tm) and were composed of compacted single crystals of lactose that were
even smaller (<1 ptm). Under these conditions it was not possible to grow a single crystal of AAP
on the surface of the spherical agglomerates. In the absence of this data, the two fastest growing
faces of AAP were selected, i.e. (001) and (111) [63].
EpiCalc was used to investigate potential lattice match between the lactose and AAP
crystal faces. The 2D lattice parameters of the crystal faces of interest were determined. The
distances and angles between concurrent lattice points for each crystal face were measured using
Mercury 3.0. Epitaxy studies were performed for 16 sets of parameters for each pair of crystal
faces. The 3 combinations of lattice parameters that showed a coincident lattice match are shown
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in Table 5-2. The V/Vo values are the minimum calculated potential values, and # is the
azimuthal angle at which the minimum V/VO value occurred.
Table 5-2: Lattice parameters for faces of AAP and lactose showing coincident lattice matches, and the minimum V/VO
value and the angle at which the minimum occurs
AAP face (001) (001) (001)
a, [A] 7.094 7.094 7.094
a2[A] 11.643 11.643 11.643
a [0] 52.46 52.46 52.46
Lactose (
Face (4 (1T (4_
bi[A] 7.878 7.878 27.531
b2 [A] 29.589 38.508 29.589
p[] 67.34 45.16 15.31
V/Vo 0.71 0.63 0.616
[ [0] 7.50 7.25 14.75
Though EpiCalc gives a fast method to test for a lattice match between two crystal faces,
it ignores favorable molecular interactions, which can also be significant in reducing nucleation
induction times. Previous studies have shown that molecular interactions can be the dominant
force rather than lattice matching [35]. Molecular dynamics simulations were performed to
explore the role that molecular functionality plays in enhancing nucleation kinetics by
influencing epitaxy. These simulations were designed to give the same information as the
EpiCalc calculations but with the inclusion of a more sophisticated energy potential energy
function to account for specific molecular interactions.
5.5. Molecular Dynamics Simulations
The results of the simulations are summarized in Figures 5-7(a)-(c). The figures show the AE of
interaction per molecule in the unit cell versus the azimuthal angle # (see Figure 2-3). The AE was
measured with reference to the total average energy of all configurations and therefore identified by how
80
much certain azimuthal angles were favored over others. This implies that direct comparisons between
systems are only qualitative.
In Figure 5-7(a), AE of interaction for the (011) face of lactose is plotted with the (001) and (111)
faces of AAP. These face pairings were aimed at representing the AAP-single crystal lactose system. The
most abundant face of lactose (determined by XRPD intensity) was chosen and paired to the fastest
growing faces of AAP. As shown in the figure, there is little variability in the interaction energy as a
function of azimuthal angle. The low variability could either be a result of all azimuthal angles strongly
interacting or all angles weakly interacting. To determine what the case might be we also analyzed the
number of hydrogen bond pairings between the faces as a function of azimuthal angle. While this analysis
cannot explain all the variability (or lack thereof) in AE it acts as a suggestive proxy for the systems in the
present study because of the high number of potential donor/acceptor pairs. The results of this analysis are
given in Figure 5-8. The number of observed hydrogen bonds for these face pairings is, on average, lower
than the other face pairings simulated. This suggests that low variability in the AE's for the (011) face of
lactose with the (001) and (111) faces of AAP is because they are interacting relatively weakly at all
azimuthal angles. This is in agreement with the relatively long nucleation induction times observed for
AAP in the presence of single crystal lactose.
In Figure 5-7(b) we have plotted three of the unique lactose/AAP face pairings that can occur in
the presence of spherical agglomerates of lactose but not the single crystal form (as determined from the
XRPD experiments). The EpiCalc calculations demonstrated the (140)/(001) and (20T)(001) pairs were
incommensurate. However the (14T)/(001) pairing showed a coincident lattice match at an azimuthal
angle of 7.25' as seen in Table 5-2. The molecular dynamics simulations also show a clear favorability for
this face pairing as indicated by the large decrease in the interaction energy. The minimum in the AE
occurs at an azimuthal angle of approximately 2.5' and not 7.25'. Though this appears to be a small
discrepancy, only a few degrees can mean the difference between coincidence and incommensurism. One
might suspect that such a small difference could be explained in terms of fluctuations in the structures as a
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result of the molecular dynamics. However, on measuring a representative pair of vectors this was found
not to be the case. On the other hand, the hydrogen bond analysis in Figure 9 suggests that the ideal
azimuthal angle for hydrogen bonding occurs at -17' for this face pairing. This suggests that the stability
minimum occurs at an angle of 2.5' because of an averaging effect of maximal hydrogen bonding and
ideal lattice coincidence - weighted in favor of coincidence. If this is the case, it demonstrates the
importance of having both molecular functionality matching and lattice matching.
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Figure 5-7: Relative Average Interaction Energy per Molecule (kJ) Between Various Crystal Faces of Lactose and AAP as
a Function of the Azimuthal Angle Between Lattice vectors
The relative importance of having both molecular functionality and lattice matching to
enhance stability is further demonstrated by the results of the hydrogen bond analysis of the
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(20T)/(00 1) faces in Figure 5-8. There is a very large maximum in the number of hydrogen bonds
occurring at an angle of approximately -5', resulting in a stability minimum in the interaction
energy of the two faces at precisely the same angle (see Figure 5-7(b)). However, while the total
number of hydrogen bonds at the maximum for the (20T)/(001) faces is greater than that of the
(14T)/(001) faces, the lack of lattice matching between the (20T) and (001) faces means the
stability minimum has a smaller depth.
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Figure 5-8: Average Number of Hydrogen Bonds Between Various Crystal Faces of Lactose and AAP as a Function of the
Azimuthal Angle Between Lattice vectors.
Previous studies have shown that lattice matching is not necessary for nucleation rate
enhancement by a substrate [35]. However, a lattice match in conjunction with matching
molecular functionality has been shown to have a greater effect on nucleation kinetics than either
of the two factors alone and is in qualitative agreement with the stability minima in Figure 5-7(b).
This is further highlighted by the results in Figure 5-7(c) where we have plotted the interaction
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energy of the (00T) face of mannitol with the (100) face of AAP, which are known to bind
together and has a similar, albeit longer, nucleation induction time. Minima in the AE are
observed at a number of angles (-120 , -75 0, 6.0 0, 41.0 0 and 130.0 0), which can be directly
related to local maxima in the number of hydrogen bonds in Figure 9. The multiple minima in
AE and their apparent strength are also in agreement with the observed low nucleation induction
time for AAP in the presence of D-mannitol.
In summary, the molecular dynamics simulations show that the interaction energy from a
system with both lattice matching and functionality matching - the pairing of the (14T)/(001)
faces - is more favorable than a system showing only functionality matching - the pairing of the
(20T)/(001) faces of lactose and AAP and the (001)/(100) faces of mannitol and AAP. Forming
spherical agglomerates of substrates is one potential way to generate new faces and potential
interactions with the crystallizing phase. This technique may provide a new way to control and
enhance nucleation kinetics.
5.6. Conclusions
Generating spherical agglomerates through emulsion crystallization is a possible method
to enact morphology changes of a substrate. This was demonstrated by crystallizing p-mannitol
and triclinic lactose as spherical agglomerates. Crystallization of acetaminophen (AAP) in the
presence of spherical agglomerates of triclinic lactose displayed enhanced nucleation kinetics
when compared to the nucleation kinetics of AAP in the presence of single crystals of triclinic
lactose. Crystallizations of AAP in the presence of spherical agglomerates and powder D-
mannitol showed little difference in the nucleation induction time. One possible explanation for
the decrease in induction time in the triclinic lactose-AAP system is the availability of new
crystal faces in the spherical agglomerates. XRPD measurements of the spherical agglomerates
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showed additional peaks that were attributed to the growth of additional crystal faces.
Calculations were performed using EpiCalc to determine the mode of epitaxy between the new
crystal faces of lactose and the fastest growing faces of AAP - the (001) and the (111) faces.
Lattice matching studies indicated that the (14T) face of lactose displayed partially coincident
lattice matching with the (001) face of AAP. Single crystal and spherical agglomerates of D-
mannitol did not show any significant difference in the available crystal faces. Furthermore,
molecular dynamics simulations confirmed that the pairing of the (1 4T)/(00 1) faces demonstrated
a far greater favourable energy interaction. These results suggest that stronger epitaxial matching
can be achieved between AAP and lactose when using spherical agglomerates. Molecular
computations indicated the epitaxy is driven by a combination of coincident lattice matching and
the formation of extensive hydrogen bonding between the two crystal faces. This work
demonstrates how the crystal morphology of a crystalline substrate is important in maximizing
the effect on nucleation kinetics and that determining the 'best' crystal face for controlling
epitaxy is paramount in the design of surfaces for control of heterogeneous nucleation.
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6. CRYSTALLIZATION AND CHARACTERIZATION OF COMPOSITE
SPHERICAL AGGLOMERATES
6.1. Introduction
Chapter 6 describes the second usage of the spherical agglomerates described in this
thesis. Rather than use the spherical agglomerates as a surface for heterogeneous nucleation as in
Chapter 5, this goal of this study was to make a crystal product using emulsion crystallization
that would be more amenable for downstream processing, for example direct compression.
Spherical particles or agglomerates have a number of physical properties that are beneficial for
downstream processing. Many materials tend to crystallize in the oil phase rather than in the
dispersed aqueous phase, however, so in order to increase kinetics, multiple materials were
crystallized into composite spherical particles. This chapter describes the combinations of
materials that were crystallized into composite spherical agglomerates, along with in-depth
characterization and an analysis of a possible mechanism for the increase in kinetics.
6.2. Single Component Spherical Agglomerates
While water-in-oil emulsion crystallizations have been used in the past to create
spherical agglomerates of glycine and glutamic acid hydrochloride [40], its versatility in terms of
application to a wide range of compounds had not yet been demonstrated. We have addressed
this issue in the current work, in which we replicated the results for glycine (Figure 2-A), and
conducted additional crystallization experiments with other small hydrophilic compounds
including lactose (Figure 2-B), sodium chloride (Figure 2-C), potassium chloride (Figure 2-D)
and D-mannitol (2-E). All experiments used the same stirring speed (650 rpm), final
crystallization temperature (800C), and mass of additive (5 w/w%), with the target compound
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concentration selected based on its solubility at 40 0C, the temperature at which the aqueous
solutions were prepared.
The optical microscope pictures indicate that the lactose and glycine spherical particles
were highly monodisperse with virtually no crystallization in the bulk, indicating no continuous
phase crystallization (Figures 6-1-A and 6-1-B). The sodium chloride and potassium chloride
crystallization experiments resulted in crystallization of single crystals of the inorganic salts
growing inside of the dispersed droplet without the formation of spherical agglomerates, as can
be seen in Figures 6-1-C and 6-1-D. For mannitol (Figure 6-1-E), however, even though there
were some spherical agglomerates, there was still a significant quantity of material that
crystallized in the bulk as needles, indicated by the thin needles that crystallized outside of the
droplets.
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Figure 6-1: Images of attempts to make spherical agglomerates. A) Glycine B) Lactose C) Sodium Chloride D) Potassium
Chloride E) Mannitol
The spherical agglomerates of glycine and lactose that were formed were further
characterized using x-ray powder diffraction. Diffraction patterns for spherical agglomerates of
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glycine, mannitol, and lactose can be seen in Figure 3. The diffraction patterns were compared to
calculated patterns for known polymorphs of the 3 materials. The agglomerates of mannitol were
exclusively beta mannitol (Figure 6-2 A), while the agglomerates of lactose were the triclinic
polymorph (Figure 6-2 A). The agglomerates of glycine were found to be a mixture of the alpha
and beta polymorph of glycine (Figure 6-2 B).
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Figure 6-2: XRPD Characterization of spherical agglomerates. Calculated patterns were compared to measured patterns
of spherical agglomerates for lactose and mannitol (Figure 6-1 A) and glycine (Figure 6-1 B)
Due to ease with which they crystallized as spherical agglomerates, lactose and glycine
were chosen as the heterosurfaces used to induce changes in the morphologies of the other
materials considered here with the goal of producing spherical agglomerates of these compounds.
Mannitol was used to demonstrate that the extent of bulk crystallization could be reduced by
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using heterosurfaces, while the morphologies of sodium chloride and potassium chloride crystals
were completely changed from individual single crystals to spherical agglomerates.
6.3. Composite Spherical Agglomerates
Crystallization experiments were conducted using a heterosurface (lactose or glycine) to
modify the morphology of the crystals formed by a target molecule (mannitol, sodium chloride,
potassium chloride) in the emulsion evaporation approach. Both components were dissolved in
the aqueous phase prior to creating the emulsion, with the concentration of each component
adjusted to ensure that the heterosurface crystallized first. Figure 6-3 shows Optical microscope
(A) and SEM images (B) of lactose/sodium chloride composite particles. It is clear that
monodisperse spherical particles were generated, and that virtually no bulk nucleation of sodium
chloride particles to form single crystals within the dispersed phase droplets was observed, in
contrast to observations of sodium chloride crystallization in the absence of the lactose
heterosurfaces. Optical microscope (Figure 6-3 C) and SEM (Figure 6-3 D) images of
lactose/potassium chloride composite particles were also taken. In these images, the particles are
again highly monodisperse, again with very little bulk nucleation of either material.
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Figure 6-3: Optical microscope (A) and SEM (B) images of composite spherical agglomerates of Lactose and Sodium
Chloride, optical microscope (C) and SEM (D) images of composite spherical agglomerates of Lactose and Potassium
Chloride
Figure 6-4 contains optical microscope (4 A and 4 C) and SEM (4 B 4 D) images of
glycine/sodium chloride and glycine/potassium chloride composite agglomerates. As seen in the
optical microscope pictures, the composite particles are again quite monodisperse. Once again,
the crystallization behavior has changed significantly. The sodium chloride did not crystallize as
single crystals inside of the emulsion droplets. The SEM images show further proof of the
spherical agglomeration of the material.
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Figure 6-4: Optical microscope (A) and SEM (B) images of composite spherical agglomerates of Glycine and Sodium
Chloride. Optical microscope (C) and SEM (D) images of composite spherical agglomerates of Glycine and Potassium
Chloride
Glycine/Mannitol composite particles are shown in Figure 6-5, where it is evident that the
majority of the crystallized material resided in the spherical agglomerates, although a small
fraction of the material crystallized in the bulk. Optical microscopy (Figure 6-5 A) suggests that
the bulk crystals were glycine rather than the needle-like mannitol crystals seen in Figure 6-1 E;
glycine particles would be prisms. The SEM images (Figure 6-5 B), again, indicate that the
majority of the material was contained in the spherical agglomerates, with no formation of bulk
needle crystals.
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Figure 6-5: Optical microscope (A) and SEM (B) images of composite spherical agglomerates of Glycine and Mannitol
6.4. XRPD characterization of composite spherical agglomerates
X-ray powder diffraction patterns of the composite spherical particles generated in these
studies were measured and compared to calculated powder patterns. The powder patterns for
composite particles of lactose and glycine with potassium chloride and sodium chloride were
compared with calculated powder patterns of potassium chloride and sodium chloride, as shown
in Figure 6-6. The characteristic peaks of the respective inorganic salts can be identified in the
diffraction pattern of each of the composite particle diffraction patterns. Combined with the
crystal morphology observed in the optical microscope and SEM images, it can be inferred that
the spherical particles contained both the template molecule and the target salt in the same
particle. The polymorphism of lactose, which crystallized as the triclinic alpha form, did not
change when it was crystallized in the presence of the inorganic salts. With glycine, however, the
crystallized polymorph changed from a mixture of alpha and beta forms for the pure compound
to a mixture of beta and gamma glycine when crystalized in the presence of the inorganic salts.
This was not an unexpected result. Glycine crystallizations from water typically results in either
the alpha or the beta form, while crystallization of glycine from solutions with increased ionic
strength often results in the gamma polymorph [79, 80].
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Figure 6-6: XRPD characterization of composite particles of glycine and lactose with inorganic salts. Calculated powder
patterns for KCI and NaCl are included for comparison
Figure 6-7 contains the XRPD patterns for crystals obtained by emulsion crystallization
with only glycine, only mannitol, and both glycine and mannitol present in the aqueous phase.
From these data, it can be seen that the diffraction pattern for the glycine/mannitol spherical
particles contains all of the major peaks observed in the patterns for both the spherical glycine
(alpha and beta forms) and the spherical mannitol (beta polymorph) particles. This is evidence
towards the crystallizations with glycine and mannitol both present resulting in agglomerates
with both glycine and mannitol.
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Figure 6-7: XRPD characterization of glycine/mannitol composite agglomerates. Black is spherical glycine, blue is
spherical mannitol, red is composite agglomerates of glycine and mannitol
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6.5. DSC Characterization of composite spherical agglomerates
Differential scanning calorimetry was used to determine whether the composite particles
contained multiple components. Because of maximum temperature of the instrument, systems
with the inorganic salts could not be analyzed. The melting points of both of the inorganic salts
are higher than 770*C, while the maximum temperature for the DSC instrument is 4000C.
Additionally, above 275C, the glycine and mannitol began to expand and cause the lids of the
DSC pans to open giving unusable data. Results for the glycine/mannitol system are shown in
Figure 6-8, where the DSC melting curves for spherical glycine, spherical mannitol, and
composite spherical particles are displayed. The composite particles contained two different
components with significantly different melting points, both of which were close to the melting
points of the spherical glycine and mannitol, respectively. The small shift the melting points of
the components of a eutectic mixture will be shifted from that of the pure components.
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Figure 6-8: DSC characterization of glycine/mannitol composite agglomerates. Melting curves for spherical glycine,
spherical mannitol, and spherical composite agglomerates are shown
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6.6. Closing
This emulsion crystallization technique has been shown to be capable of generating
spherical agglomerates of aqueous soluble materials. This study has shown that by using
heterosurfaces as templates, composite spherical agglomerates can be made using materials that
otherwise crystallize as single crystals in the emulsion droplets. This crystallization technique
could potentially be expanded to the crystallization of composite particles containing larger
organic molecules, including API's to enhance their mechanical properties. There is a need to
characterize the physical properties of the composite particles i.e. compressibility, dissolution, or
flowability, more fully in order to assess whether further process development would be
beneficial. Finally, new technologies must be developed to scale up these approaches for use in
actual manufacturing process.
6.7. Conclusions
Crystal morphology is a significant factor in the ease of processing of active
pharmaceutical ingredients, with spherical particles or agglomerates having particularly
favorable properties. This work has explored using heterosurfaces to modify the morphology of a
crystallizing phase to form spherical agglomerates. Single component experiments showed that
lactose and glycine could be crystallized successfully as spherical agglomerates, while potassium
and sodium chloride crystallized as single crystals in the emulsion droplets. D-mannitol
crystallized as spherical agglomerates, though with larger amounts of bulk crystallization than
lactose or glycine. Lactose and glycine crystals were used as heterosurfaces, for the nucleation of
D-mannitol, potassium chloride, and sodium chloride crystals with morphology modification.
The combinations of lactose and glycine with the inorganic salts resulted in monodisperse
composite agglomerates, as confirmed through x-ray powder diffraction and image analysis.
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Crystallizing glycine and mannitol together also resulted in composite spherical agglomerates, as
confirmed through x-ray powder diffraction, image analysis, and differential scanning
calorimetry.
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7. CONCLUSIONS AND FUTURE WORK
7.1. Conclusions
This thesis encompassed two major areas of research. The first area was about process
development of continuous crystallizations using existing technology as part of an effort to
develop continuous manufacturing for pharmaceuticals. The second area was to research new
technologies and methods that could simplify and improve crystallization processes. Though
they are greatly different projects, both of these areas are of vast importance to developing and
implementing continuous manufacturing throughout the pharmaceutical industry.
Two different continuous crystallization processes were developed for the continuous
manufacturing unit. The first process was an anti-solvent crystallization for intermediate
purification. The second process was a reactive and cooling crystallization for the generation and
isolation of the final product. There were significant technical challenges to overcome for both of
these process development steps, but both were successfully developed and implemented into the
bench-scale continuous manufacturing unit. Population and mass balances were used to model
both of the crystallizations and extract important kinetic parameters. Distribution coefficients
were also measured and included in the modeling. The distribution coefficients and kinetics
parameters were used to simulate how changing various operating parameters would affect the
crystallization yield and purity.
Two separate projects using spherical agglomerates were also researched. The first
project studied the effects of morphology changes (due to crystallizing substrates as spherical
agglomerates rather than as single crystals) on nucleation kinetics. Spherical agglomerates of
lactose were found to have significantly different surface morphology as well as the growth of
new crystal faces. Additionally, crystallizations of AAP in the presence of spherical
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agglomerates of lactose were found to have faster nucleation kinetics than crystallizations of
AAP in the presence of single crystal lactose. An epitaxy study between the new crystal faces of
lactose and the fastest growing faces of AAP was performed. Molecular dynamics simulations
were performed to measure the energy interactions between the various faces. The most stable
pairing of faces ((141)/(001)) was also the pair that showed the most favorable lattice match
from the epitaxy study. Generating nucleation substrates as spherical agglomerates is a potential
way for pre-processing of materials to improve crystallization processes.
The second study looked at making composite spherical agglomerates for downstream
manufacturing purposes. Many materials cannot be crystallized as spherical agglomerates using
conventional techniques. This study aimed to use heterosurfaces to template the nucleation of
model compounds into spherical agglomerates. Glycine and lactose were used as heterosurfaces
to template the nucleation of sodium chloride, potassium chloride, and mannitol and modify their
morphology into spherical agglomerates. These agglomerates were characterized using image
analysis, x-ray powder diffraction, and differential scanning calorimetry.
7.2. Future outlook
The results of this study have shown both that existing technologies are viable for
continuous crystallization process development and that new techniques and methods can be
developed to improve said crystallization processes. Though the process development work itself
was a success, there is still some room for improvement and further research. In order to improve
process yields, adding in recycle streams would be greatly beneficial. Though it comes at a
potential cost with regards to purity (as soon from the modeling results), if carefully done,
adding in combined evaporation and recycle step into the second vessel could result in
significantly higher yields for both of the crystallizations. The crystallization for the Aliskiren
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boc-base would be more difficult to design, as the solvent is a mixed solvent and thus the
evaporation would have to be more finely controlled. Additionally, developing online process
analytical technology to perform real time monitoring of the crystallizations would be beneficial.
Attempts were made to use both mid-IR and NIR spectroscopic probes inside of the crystallizers
as well as online FBRM measurements. The main issue with those was that the probe window
was clogged by the slurry, preventing any measurements. There were a few potential research
tools that could automatically clean the probe window, but further investigation into new
methods would be of great help. Finally, the modeling was performed using a 1-dimensional size
model. The crystals from both of the crystallizations were in fact needles, which cannot truly be
defined by a 1 dimension. The development of a more complex 2-dimensional model for the
crystallization would be beneficial in order to more accurately describe the behavior of the
crystallization.
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